Scientists have found that proteins at the blood-brain barrier tend to pump out riluzole, the only FDA-approved drug for Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, limiting the drug's effectiveness, through research in mice. However, when the investigators blocked these proteins, the effectiveness of riluzole increased and the animals experienced improved muscle function, slower disease progression and prolonged survival. The findings suggest that ...
Read More
No comments:
Post a Comment